TroyGould advises Lixte Biotechnology Holdings, Inc. in its $5.8 million registered direct offering.
TroyGould represented Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) in a recent $5.8 million registered direct offering under which the company issued 2,900,000 shares of common stock at a purchase price of $2.00 per share. Lixte Biotechnology is a clinical-stage pharmaceutical company focused on new targets for cancer drug treatment. The company intends to use net proceeds from the offering for continuing operating expenses and working capital, including to further clinical development of its lead compound, LB-100. WestPark Capital, Inc. and WallachBeth Capital, LLC acted as co-placement agents for the offering. The TroyGould team was led by David Ficksman. For more information, see this press release.
Celebrating 50 years of success as one of Southern California’s leading business law firms, TroyGould is recognized in the U.S. and abroad for its success in helping both U.S. and non-U.S entities and individuals achieve their business goals. The firm’s transactional and litigation clients range from emerging companies to middle-market and Fortune 500 companies across a diverse set of industries including life sciences, technology, entertainment/media, manufacturing, food and beverage, real estate, consumer products and health care. For more information, visit TroyGould.com.